Generated by Codex with GPT 5.6 Sol XHigh

This summary covers The Economist’s July 4th, 2026 Science & technology article listed in the contents as Probing black holes and published under the headline Digging deeper.

Black holes are defined by a boundary that cannot be seen directly: the event horizon, beyond which even light cannot escape. A remarkably clear gravitational-wave signal has now let physicists examine that boundary through its effects on spacetime. The result agrees precisely with Albert Einstein’s general theory of relativity and opens a new way to search for physics beyond it.

Generated by Codex with GPT 5.6 Sol XHigh

This summary covers The Economist’s July 4th, 2026 Science & technology article listed in the contents as Sequencing babies' genomes and published under the headline The genomic generation.

Sequencing a newborn’s entire genome could reveal serious illnesses before symptoms appear, when treatment has the best chance of working. It could also burden healthy children with frightening predictions that never come true and place their most intimate data at risk for life. The article argues that the technology’s medical promise is real, but the case for universal screening depends on choosing carefully what to report, how to explain uncertainty and whether diagnosis should be tied to long-term research.

Generated by Codex with GPT 5.6 Sol XHigh

This summary covers The Economist’s July 4th, 2026 Science & technology article listed in the contents as Synthetic biology and published under the headline A design for life.

Researchers have assembled cells that can grow, reproduce and evolve without inheriting any working parts from earlier life. The creations, called SpudCells, are still fragile and dependent on an artificial environment. Yet their importance lies precisely in how little they can do: every component was deliberately added, giving scientists an unusually clear view of how biological machinery works.

Generated by Codex with GPT 5.6 Sol XHigh

This summary covers The Economist’s July 4th, 2026 Leaders article listed in the contents as The government and AI and published under the headline Rules for supermodels.

Frontier artificial intelligence is becoming too capable to release casually and too useful to lock away indefinitely. The article argues that governments need a durable system for managing that tension before a model enables a major cyberattack, helps a bioterrorist or causes some other disaster. America has begun regulating releases, but its improvisational approach shows why clearer institutions are urgently needed.

Generated by Codex with GPT 5.6 Sol XHigh

This summary covers The Economist’s June 20th, 2026 Science & technology article listed as The biggest El Niño ever? and published under the headline Boy problems.

A new El Niño has begun, and climate forecasters think it could be the strongest in the modern record. The article’s warning is not simply that the planet may become hotter in 2027. El Niño redistributes heat and rainfall around the world, so an exceptionally powerful event could turn existing drought, hunger and conflict into overlapping humanitarian crises.

Generated by Codex with GPT 5.6 Sol XHigh

This summary covers The Economist’s June 20th, 2026 Science & technology article listed as Ancient plagues and published under the headline Biology's plague journal.

Plague left more than mass graves and historical fear. It also left genetic evidence inside human teeth. The article explains how scientists are using that ancient DNA to reconstruct the disease’s evolution, identify outbreaks that written history never recorded and challenge the idea that plague needed crowded cities to become catastrophic.

Generated by Codex with GPT 5.6 Sol XHigh

This summary covers The Economist’s June 20th, 2026 Britain article listed as The AI opportunity and published under the headline A player or a spectator?.

Britain has many of the ingredients for a successful artificial-intelligence industry: strong research, experienced founders, abundant venture capital and a government more willing than the European Union to let firms experiment. Yet the article’s central warning is that potential is not the same as power. Unless Britain turns its scientific strengths into infrastructure, companies and widespread adoption, it may watch the AI revolution from the sidelines.

Generated by Codex with GPT 5.6 Sol XHigh

This summary covers The Economist’s June 20th, 2026 Finance & economics article listed in the contents as AI-pilled economists and published under the headline The new-seekers.

Artificial intelligence may reshape work, productivity and economic growth, yet many academic economists have been slow to study it. The article argues that the centre of AI economics is consequently moving away from universities and toward government agencies, think-tanks and the AI labs themselves. That shift gives researchers better data and closer contact with the technology, but it also risks putting important public questions inside institutions with commercial interests and limited incentives to share what they learn.

Generated by Codex with GPT-5

This summary covers The Economist’s June 20th, 2026 Business article listed in the contents as Big bills for tokenmaxxing and published under the headline Token reckoning.

Artificial intelligence is creating a new corporate headache: the more useful AI agents become, the harder their costs are to control. These systems do more than answer a prompt. They reason through several steps, call tools and sometimes create other agents, consuming large numbers of tokens - the units of text that AI companies commonly use for billing. As agents spread across the many software products used by a large company, small charges can compound into an enormous bill.

Generated by Codex with GPT-5

This summary covers The Economist’s June 20th, 2026 Science & technology / Well Informed article listed in the contents as A cancer breakthrough and published under the headline Has one of cancer's master switches been found?.

Pancreatic cancer is one of medicine’s hardest targets: it is aggressive, often detected late and usually resists immunotherapy. The article argues that a new drug, daraxonrasib, matters because it has produced a rare and meaningful gain against that disease while also pointing toward a broader class of cancer treatments.